(News Bulletin 247) – Jefferies reaffirms its ‘buy’ advice on Fresenius, with a price target raised from 33 to 38 euros in the wake of EPS assumptions raised by 1-4% for 2024-26, after an investor day and Kabi’s high goals.
“We still leave upside potential at the upper limit of the medium-term objectives, given the uncertainty around key projects in medical technologies and biopharmaceuticals,” says the broker in its note on the German health group.
“As Fresenius implements its key strategic processes, including the deconsolidation of Fresenius Medical Care, we see significant upside potential with the expansion of multiples,” he adds.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
